Chengdu Kanghua Biological Products

300841 · SHE · Healthcare / Biotechnology

47.49CNY-1.49 (-3.04%)

Price History

Full chart

Market Stats

Previous Close48.98

Open49.00

Day Range47.46 – 49.37

52-Week Range42.31 – 85.59

Volume2.02M

Market Cap7.32B

P/E (TTM)29.66

Forward P/E0.00

EPS1.90

Dividend Yield0.89%

Beta0.41

50-Day Avg50.37

200-Day Avg57.52

About

Chengdu Kanghua Biological Products Co., Ltd. engages in the research, development, and operation of biological products in China. It offers freeze-dried human rabies vaccines; ACYW135 meningococcal polysaccharide vaccine. The company was founded in 2004 and is based in Chengdu, China.

Company Details

SectorHealthcare
IndustryBiotechnology
CEOMr. Wennian Wu
Employees550
HeadquartersNo. 182, Beijing Road, Chengdu, China, 610100, China
Websitehttps://www.kangh.com

Leadership

Mr. Wennian WuVP & Secretary · b. 1983
Mr. Huaigong ChenVP & Quality Manager · b. 1972
Mr. Fu WangVice President · b. 1969
Ping LiuAccounting Supervisor

Financials

Income Statement

Currency: CNY	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	71.07M	92.92M	261.93M	559.47M	554.64M	1.04B	1.29B	1.45B	1.58B	1.43B	1.17B
Growth (%)	-	+30.74%	+181.90%	+113.59%	-0.86%	+87.26%	+24.44%	+11.94%	+9.03%	-9.23%	-18.64%
Cost of Revenue	13.28M	16.59M	29.24M	36.74M	34.46M	62.81M	85.70M	101.84M	104.90M	84.64M	92.80M
Gross Profit	57.79M	76.33M	232.69M	522.72M	520.17M	975.83M	1.21B	1.34B	1.47B	1.35B	1.07B
Gross Margin	81.31%	82.15%	88.84%	93.43%	93.79%	93.95%	93.37%	92.96%	93.35%	94.09%	92.03%
Operating Expense	44.29M	69.59M	141.78M	333.09M	296.77M	490.77M	290.99M	659.38M	895.88M	879.96M	799.09M
Operating Income	13.49M	6.73M	90.91M	189.63M	223.40M	485.06M	915.76M	685.50M	576.61M	467.28M	273.12M
Operating Margin	18.99%	7.25%	34.71%	33.89%	40.28%	46.70%	70.85%	47.38%	36.55%	32.63%	23.44%
EBITDA	34.76M	26.38M	104.54M	198.32M	228.61M	478.18M	629.00M	643.37M	651.50M	595.04M	340.19M
EBITDA Margin	48.90%	28.39%	39.91%	35.45%	41.22%	46.04%	48.67%	44.47%	41.30%	41.56%	29.20%
Net Income	11.70M	6.66M	74.46M	154.14M	186.69M	408.05M	829.48M	598.07M	509.22M	398.65M	219.90M
Net Income Margin	16.47%	7.17%	28.43%	27.55%	33.66%	39.29%	64.18%	41.34%	32.28%	27.84%	18.88%
R&D	5.01M	6.36M	4.27M	18.92M	22.79M	58.25M	78.88M	179.94M	253.03M	132.05M	118.39M
R&D as % of Total Revenue	7.05%	6.84%	1.63%	3.38%	4.11%	5.61%	6.10%	12.44%	16.04%	9.22%	10.16%
Interest Expense	11.56M	10.11M	5.12M	457.08K	532.84K	230.79K	72.69K	3.34M	4.81M	5.38M	3.68M
Interest Expense % of Total Revenue	16.27%	10.88%	1.96%	0.08%	0.10%	0.02%	0.01%	0.23%	0.30%	0.38%	0.32%

Balance Sheet

Currency: CNY	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	169.74M	201.01M	274.74M	486.07M	689.14M	2.15B	3.02B	3.71B	4.21B	4.03B	4.01B
Total Liabilities	272.61M	297.23M	86.38M	118.37M	114.49M	173.24M	347.74M	635.40M	695.22M	580.07M	472.31M
Total Equity	-102.87M	-96.21M	188.37M	367.70M	574.65M	1.97B	2.67B	3.08B	3.51B	3.45B	3.54B
Cash	9.05M	9.85M	62.58M	92.36M	241.63M	1.15B	926.88M	651.46M	1.04B	1.00B	1.15B
Total Debt	659.70K	416.40K	7.50M	19.00M	10.00M	2.34M	900.52K	126.35M	190.91M	186.89M	-
Net Debt	-8.39M	-9.43M	-55.08M	-73.36M	-231.63M	-1.14B	-925.98M	-525.11M	-848.45M	-814.44M	-

Cash Flow

Currency: CNY	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	6.51M	2.64M	89.96M	57.35M	182.73M	369.56M	130.33M	194.99M	573.98M	572.24M	379.71M
Investing Cash Flow	-3.07M	-1.86M	-4.38M	-34.58M	-23.97M	-441.40M	-201.53M	-412.46M	-163.39M	-341.87M	-
Financing Cash Flow	-	-	-32.81M	7.00M	-9.53M	975.75M	-147.40M	-73.56M	-7.12M	-471.79M	-
Capital Expenditure	3.07M	1.86M	4.53M	34.58M	24.04M	135.67M	314.94M	419.23M	157.27M	144.30M	70.79M
Free Cash Flow	3.43M	787.83K	85.43M	22.77M	158.69M	233.90M	-184.61M	-224.24M	416.71M	427.94M	308.92M
Dividends Paid	-	-	21.27M	5.94M	532.84K	230.79K	90.00M	133.78M	71.63M	267.83M	136.43M
FCF to OCF	52.80%	29.80%	94.96%	39.71%	86.85%	63.29%	-141.66%	-115.00%	72.60%	74.78%	81.36%
Dividend Paid to FCF	-	-	24.90%	26.09%	0.34%	0.10%	-48.75%	-59.66%	17.19%	62.58%	44.16%

Earnings

Report Date	Apr 27, 2020	Aug 24, 2020	Oct 21, 2020	Dec 31, 2020	Apr 19, 2021	Aug 2, 2021	Oct 25, 2021	Dec 31, 2021	Apr 21, 2022	Aug 22, 2022	Oct 24, 2022	Mar 29, 2023	Apr 24, 2023	Aug 22, 2023	Oct 20, 2023	Jan 30, 2024	Apr 23, 2024	Aug 17, 2024	Oct 28, 2024	Apr 18, 2025	Aug 27, 2025	Oct 17, 2025	Apr 28, 2026	Aug 18, 2026
EPS Estimate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EPS Actual	0.96	1.16	1.19	0.48	0.40	2.51	2.45	1.82	1.01	1.35	1.25	0.86	0.79	1.07	0.90	1.02	1.12	1.19	0.76	-0.06	0.72	0.57	0.24	0.88
Surprise	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Timing	After-hours	After-hours	Pre-market	-	After-hours	Pre-market	Pre-market	-	Pre-market	After-hours	Pre-market	After-hours	Pre-market	After-hours	Pre-market	After-hours	Pre-market	-	Pre-market	After-hours	-	-	-	-

Key Statistics & Ratios

Market Cap7.32B

Enterprise Value6.26B

Trailing P/E29.66

Forward P/E0.00

Price / Sales6.01

Price / Book2.01

EPS1.90

Book Value27.81

Revenue (TTM)1.22B

Gross Profit (TTM)1.09B

EBITDA345.37M

Profit Margin20.22%

Operating Margin32.42%

Return on Equity7.00%

Return on Assets4.39%

Shares Outstanding129.95M

Shares Float86.12M

Beta0.41

Dividend Yield0.89%

Dividend Rate0.50

Payout Ratio29.65%

Dividends

20261×

0.50May 29, 2026

20251×

1.00May 20, 2025

20241×

2.00May 8, 2024

20231×

0.50May 24, 2023

20221×

1.50May 25, 2022

20211×

0.67May 27, 2021

Stock Splits

May 25, 20221.5:1
May 27, 20211.5:1